Low doses of the generic steroid dexamethasone in patients admitted to hospital with COVID-19 reduced the mortality rate among those with the most severe cases of infection by about a third. This was shown by the data from the study on Tuesday.
The results, dubbed "major breakthroughs" by scientists who led the UK clinical trial RECOVERY, suggest that the drug should immediately become standard care in hospitalized pandemic patients, said the researchers.
"This is a result that shows that patients with COVID-19 who are ventilated or given oxygen receive dexamethasone, save lives and at a remarkably low cost," said Martin Landray, Oxford University Professor, who is co-leader of the study.
Co-lead researcher Peter Horby said dexamethasone – a generic steroid that is often used to reduce inflammation in other diseases – was "the only drug that has been shown to reduce mortality – and it reduces it." considerably. "
"It's a big breakthrough," he said.
There are currently no approved treatments or vaccines for COVID-19, the disease caused by the new coronavirus, which has killed more than 4.31,000 people worldwide.
(Except for the headline, this story was not edited by NDTV staff and published from a syndicated feed.)